

EXPRESS MAIL NO. EV348172541US

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(To be used for all correspondence
after initial filing)

Application Number	10/015,540
Filing Date	December 11, 2001
First Named Inventor	Nicholas Ling
Group Art Unit	1631
Examiner Name	Michael Borin, Ph.D.
Attorney Docket No.	690068.405C3

RECEIVED

SEP 15 2003

TECH CENTER 1600/2900

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input checked="" type="checkbox"/> Drawing(s)	<input type="checkbox"/> CD(s), Number of CD(s) _____
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Request for Corrected Filing Receipt	<input type="checkbox"/> After Allowance Communication to Group
<input checked="" type="checkbox"/> Amendment/Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Declaration	<input checked="" type="checkbox"/> Return Receipt Postcard
<input type="checkbox"/> Information Disclosure Statement; Form PTO-1449	<input type="checkbox"/> Statement under 37 CFR 3.73(b)	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Cited References	<input type="checkbox"/> Terminal Disclaimer	CRF; Declaration regarding
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	Sequence Listing; Paper Copy of
<input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53		Sequence Listing (4 pages)
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	William T. Christiansen, Ph.D.	Customer Number	00500
Signature			
Date	September 10, 2003		

VIA EXPRESS MAIL

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Nicholas Ling et al.
Application No. : 10/015,540
Filed : December 11, 2001
For : METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS
USING PEPTIDE ANALOGUES OF HUMAN M **RECEIVED**
PROTEIN

SEP 15 2003

Examiner : Michael Borin, Ph.D. **SEP 15 2003**

Art Unit : 1631

Docket No. : 690068.405C3

SEP 15 2003

Date : September 10, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT AND
PRELIMINARY AMENDMENT

Commissioner for Patents:

In response to the Restriction Requirement dated August 11, 2003, Applicants respectfully traverse and submit that by the amendments accompanying this response make the required restriction moot. In pertinent part, claim 45 has been amended to add the term "consecutive". Applicants respectfully submit that by such an amendment, claim 45 and the claims depending therefrom clearly fall within Group I. However, if the Examiner should find this traversal ineffective for any reason, Applicants hereby elect, with traverse, Group I, claims 30-34, 73 and 74, for examination at this time.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 4 of this paper.